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Abstract: Low-dose radiation hypersensitivity (HRS) describes a phenomenon of excessive sensitivity to X ray doses 
0.5 Gy. Docetaxel is a taxane shown to arrest cells in the G2/M phase of the cell cycle. Some previous studies suggested 
that HRS might result from the abrogation of the early G2 checkpoint arrest. First we tested whether HRS occurs in gastric 
cancer—derived cells, and whether pre-treatment of cells with low docetaxel concentrations can enhance the magnitude of 
HRS in gastric cancer cells. The results demonstrated HRS at ∼0.3 Gy and the synergy between 0.3 Gy and docetaxel 
(3 nM for 24 h), and the additivity of other drug/dose combinations. The synergistic effect was associated with a signiﬁ  cant 
docetaxel-induced G2 accumulation. Next, we evaluated in time-course experiments ATM kinase activity and proteins 
associated with the induction and maintenance of the early G2 checkpoint. The results of multi-immunoblot analysis dem-
onstrate that HRS does not correlate with the ATM-dependent early G2 checkpoint arrest. We speculate that G2 checkpoint 
adaptation, a phenomenon associated with a prolonged cell cycle arrest, might be involved in HRS. Our results also suggest 
a new approach for the improvement the effectiveness of docetaxel-based radiotherapy using low doses per fraction.
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Introduction
Worldwide, gastric cancer is the fourth most common malignancy and the second most fatal (Alberts 
et al. 2003; Edwards et al. 2006). Signiﬁ  cant geographic variation exists with high-risk areas including 
Japan and Europe, and low risk areas including the United States (Alberts et al. 2003). Despite its 
relatively low incidence in the United States, gastric cancer is a signiﬁ  cant cause of morbidity and 
mortality, with 23,000 cases per year, resulting in 13,000 deaths. At time of diagnosis, approximately 
60% to 75% patients with gastric cancer have advanced disease with a ﬁ  ve-year survival rate ranging 
from 3% to 22%, depending on the extent of the disease (Edwards et al. 2006). The available clinical 
data in the treatment of gastric carcinoma have demonstrated that radiation therapy has a role for improv-
ing local control and, in combination chemotherapy, survival (Alberts et al. 2003; Edwards et al. 2006; 
Das and Ajani, 2005).
Several drugs belonging to different classes have been proven active in patients with gastric cancer 
(Alberts et al. 2003; Das and Ajani, 2005). Clinical results have been reported for antimetabolites, 
platinum-based agents, DNA topoisomerase inhibitors and more recently taxanes. However, about half 
of patients are resistant to chemotherapy. Another limitation is cumulative, systemic toxicity after 
typical prolonged and high-dose drug therapy that often compromises “full-dose” therapy (Alberts et al. 
2003; Das and Ajani, 2005; Oehler and Ciernik, 2006). The role of standard radiotherapy in the treat-
ment in gastric cancers remains controversial because of the marked radiation sensitivity of neighbor-
ing organs (Oehler and Ciernik, 2006). A great deal of interest has focused on the search of new 
strategies to enhance the anticancer effects of lower drug and/or radiation doses.
A recent multiinstitutional Phase I study evaluated the efﬁ  cacy of low dose fractionated radiation 
therapy (0.6 Gy per fraction, two fractions per day) in combination with gemcitabine in patients with 
gastrointestinal cancers (Regine et al. 2007). This successful strategy for the delivery of upper abdominal 302
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radiation has been based on experimental data 
demonstrating the low dose radiation hypersensi-
tivity (HRS) phenomenon i.e. a statistically sig-
niﬁ  cant disagreement between predictions of the 
linear-quadratic model and measurements of cell 
survival after radiation doses of less 1 Gy (Marples 
and Joiner, 1993; Short and Joiner, 1998; Short 
et al. 1999; Joiner et al. 2001). According to these 
reports, the linear-quadratic model (Kellerer and 
Rossi, 1972) overestimates survival in the low dose 
range (Joiner et al. 1993). Studies with cells in 
speciﬁ  c cell cycle phases demonstrated that HRS 
response is more prominent in G2/M phase cells, 
compared to that in the asynchronous population 
(Marples et al. 2003; Short et al. 2003). It has been 
proposed that enhanced sensitivity of G2/M phase 
cells to low radiation doses is associated with the 
abrogation of the early G2 checkpoint responses 
including a failure to delay entry into mitosis and 
to initiate DNA repair (Marples et al. 2003; Short 
et al. 2003). The early G2 checkpoint is ATM 
dependent, speciﬁ  c to cells irradiated at G2 and 
transient, resolving within 1 h after irradiation. A 
hallmark of the early G2 checkpoint is a rapid 
reduction in mitotic index (Xu et al. 2001, 2002). 
The late G2 checkpoint is activated in cells irradi-
ated in G1 and S, is ATM independent and sus-
tained, and begins to manifest only several hours 
after irradiation. A hallmark of the late G2 check-
point is an accumulation of cells in G2. The late G2 
checkpoint has not been directly implicated in HRS 
responses.
4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β, 
10β-trihydroxy-9-oxotax-11-ene-11α-(2R, 3S)-3-
tert-butoxycarbonylamino-2-hydroxy-3-phenyl-
propionate (RP 56976A; docetaxel) is a 
microtubule-stabilizing taxane, which has recently 
been approved for use in the clinic for the treatment 
of advanced gastric malignancies (Das and Ajani, 
2005). Preclinical studies demonstrated that 
docetaxel is active against gastric cancer cells as 
a single agent or in combination with antimetabo-
lites or radiation (Ricotti et al. 2003; Balcer-
Kubiczek et al. 2006). The biological rationale for 
combination therapy with docetaxel has been based 
on the cell cycle effects of the drug, speciﬁ  cally its 
well-established ability to accumulate cells at the 
G2/M phase (Ricotti et al. 2003; Abal et al. 2003; 
Morse et al. 2005; Hernández-Vargas et al. 2007). 
The primary mechanism of docetaxel action is 
mitotic spindle damage (reviewed by Abel et al. 
2003). Recent mechanism-of-action studies 
demonstrated different mitotic responses according 
to drug concentration (Ricotti et al. 2003; Abal 
et al. 2003; Morse et al. 2005; Hernández-Vargas 
et al. 2007). High clinically irrelevant concentra-
tions induce a permanent mitotic arrest (Ricotti 
et al. 2003; Abal et al. 2003; Hernández-Vargas 
et al. 2007). By contrast, clinically relevant con-
centrations interfere with mitotic progression by 
transiently activating the spindle checkpoint, with-
out signiﬁ  cantly arresting cells at M-phase (Abal 
et al. 2003; Morse et al. 2005; Balcer-Kubiczek 
et al. 2006; Hernández-Vargas et al. 2007).
Against this background, we initiated a pre-
clinical study to determine whether HRS occurs in 
gastric cancer—derived cells, and whether pre-
treatment of cells with low docetaxel concentrations 
can enhance the magnitude of HRS response. In 
addition, we evaluated six proteins associated with 
the induction and maintenance of the early G2 
checkpoint. The radiation-induced G2 DNA damage 
checkpoint operates at least in part by maintaining 
phosphorylation of the checkpoint protein kinase 1 
(Chk1), a modification that prevents the cycle 
division cycle 25C (Cdc25C) phosphatase from 
activating the cyclin-dependent protein kinase 1 
(Cdk1; also called Cdc2) (Furnari et al. 1997; 
Sanchez et al. 1997; Peng et al. 1997). An initiating 
event for this pathway is transient phosphorylation 
of ataxia telangiectasia mutated (ATM) protein on 
serine (S) 1981 (Bakkenist and Kastan, 2003). The 
inability of cells to maintain G2 checkpoints 
correlates with the inability to maintain phosphor-
ylations of S317 on Chk1, S216 on Cdk25C, 
tyrosine (Y) 15 on Cdk1 (Sanchez et al. 1997; Peng 
et al. 1997; Gatei et al. 2003; Syljuåsen et al. 2003). 
We completed our evaluation of the G2 checkpoint 
by assessing the expression of cyclin B1 and phos-
phorylation of S10 in histone H3. S10 phosphory-
lation begins late in G2, is complete in prophase 
and absent during the anaphase/telophase transition 
(Juan et al. 1998; Prigent and Dimitrov, 2003). 
Cyclin B1 is expressed throughout mitosis (Juan 
et al. 1998). Cyclin B1 and/or H3 S10 were previ-
ously used to identify mitotic cells after various 
treatments (Juan et al. 1998; Xu et al. 2002; Marples 
et al. 2003; Deckbar et al. 2007). Phosphorylation 
of ATM S1981, Chk1 S317 or Cdk1 expression 
were studied previously in the context of molecular 
effects of low radiation doses including HRS 
(Marples et al. 2003; Bakkenist and Kastan, 2003; 
Enns et al. 2004; Buscemi et al. 2004; Short et al. 
2005; Deckbar et al. 2007).303
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Materials and Methods
Cell lines and cell culture
Three cell lines tested for the presence of HRS 
were established from the following tumors: 
untreated gastric adenocarcinoma (AGS), non-
small cell lung adenocarcinoma (A549) and 
androgen-independent prostate carcinoma (PC3) 
(obtained from the American Type Culture Collec-
tion, Manassas, VA, U.S.A.). HRS was demon-
strated previously in the A549 and PC3 cell lines 
(Joiner et al. 2001; Enns et al. 2004); in the present 
experiments these cell lines served as positive 
controls for our clonogenic assay methodology. 
Cells were grown as attached monolayers in the 
F12 Kaighn’s medium supplemented with 10% 
fetal bovine serum and without antibiotics.
Docecetaxel treatment
Docetaxel (Taxotere
®; lot 0002820; MW = 807.9 
g/mol) obtained from Aventis Pharmaceuticals, a 
member of sanoﬁ  -aventis Group (Bridgewater, NJ, 
U.S.A.) in a pure crystalline powder form was 
stored in sterile dimethylsulfoxide (DMSO); 99.9% 
pure; Sigma; St. Loius, MO, U.S.A.) as 100 µg/ml 
solution at −20 °C. Stock solution was diluted to 
the required concentrations in the nM-range by 
successive dilutions in DMSO and in growth 
medium; similarly diluted DMSO was used to carry 
out mock drug exposure (Balcer-Kubiczek et al. 
2006). Drug treatments with or without subsequent 
X-irradiation were performed as in previous stud-
ies (Balcer-Kubiczek et al. 2006).
X-irradiation
Cells were irradiated with single doses between 
0.05 and 6 Gy using a Pantak machine (250 kV, 
13 mA with a 0.5-mm Cu + 1-mm Al filter) 
producing X-rays at a dose rate of 0.3 Gy min
−1 
(SSD = 82 cm) or 2.4 Gy min
−1 (SSD = 32 cm). 
The lower dose rate was used for doses  0.5 Gy.
Survival experiments with graded 
doses of X-rays
To test for the presence of HRS, stock cultures 
of AGS, A549 and PC3 cells were established 
two days before X-irradiation, then dissociated 
using 0.25% trypsin/0.05% EDTA solution, 
counted electronically and diluted to the required 
concentrations depending on the expected surviving 
fraction after irradiation. Our previously published 
AGS, A549 and PC3 cell survival curves were used 
to plan dilutions for groups to be irradiated with 
doses 1 Gy (Balcer-Kubiczek et al. 1999, 2006, 
2007). A surviving fraction of 1 was assumed for 
groups to be irradiated with doses 1 Gy (i.e. equal 
cell numbers were plated in control and dose 
groups). Three to ﬁ  ve 100-mm culture dishes were 
plated from subculture for each dose. Dishes were 
incubated overnight at 37 °C prior to X-irradiation 
for exponential growth recovery. Following irra-
diation, cells were returned to incubators for 
14–21 days to allow full development of surviving 
colonies in all dose groups. The growth medium 
was renewed weekly. At the end of incubation 
period colonies were stained with 1% crystal vio-
let in ethanol, and manually counted for surviving 
fraction determinations by a standard colony for-
mation assay (Puck and Marcus, 1956). Up to 15 
replicate experiments were performed at doses 
ranging from 0.05 to 10 Gy
Survival experiments with single
X-ray doses alone or in combination 
with docetaxel
To test for interaction between docetaxel and X-
irradiation, AGS cells were plated as above. After 
overnight incubation the medium was removed and 
replaced with the medium containing 0 (0.05% 
DMSO) or 3 nM docetaxel. Cells were irradiated 
with 0, 0.3 or 2 Gy of X-rays at 0, 4 or 24 h after 
the initiation of drug treatment. Immediately 
(10 min) following X-irradiation cells were 
returned to normal drug-free growth medium, as 
described before (Balcer-Kubiczek et al. 2006). 
Clonogenic survival was determined as described 
above in the previous section. Replicate experi-
ments, each comprising of 18 experimental groups 
(i.e. three time points times three X-ray doses with 
0 or 3 nM docetaxel), were performed 15 times.
Statistical analysis of survival data
Survival data sets for each of the three cell lines 
tested for the presence of low-dose HRS were ﬁ  t-
ted to the basic two-parameter linear-quadratic 
(LQ) model (Kellerer and Rossi, 1972) as well as 
to the four-parameter induced-repair (IR) model 
(Joiner et al. 1993); for the explicit equation and 
interpretation of IR model parameters see 304
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Short et al. (1999). The LQ or IR model best-ﬁ  t 
parameters in Table 1 were obtained using Sigma-
Plot software, version 6.10 (SystatSoftware, Inc. 
San Jose, CA, U.S.A.) and, independently, using 
JPM
® SAS software (Cary, NC, U.S.A.) (data not 
shown). The two non-linear least-squares regres-
sion routines utilize different iterative methods (the 
Marquardt-Levenberg algorithm in SigmaPlot or 
the Gauss-Newton algorithm in JPM
® SAS soft-
ware). HRS was judged to be present if the ratio 
of the survival curve slope measured at low doses 
(αs) to the slope extrapolated from the high-dose 
response (αr) was statistically different from one 
and the dose (dc) at which a local survival minimum 
occurs was statistically different from zero (9). 
Graphical presentation of IR or LQ equations with 
SigmaPlot best-ﬁ  t parameters for each of the three 
cell lines was obtained using Physics Analysis 
Workstation software (CERN Program Library; 
CERN, Geneva, Switzerland; http://paw.web.cern.
ch/paw/).
In combined experiments, the surviving frac-
tions after different radiation doses were normal-
ized to the toxicity of docetaxel when given alone, 
as described previously (Balcer-Kubiczek et al. 
2006). At each time point the survival fraction after 
radiation dose without docetaxel was compared to 
the normalized surviving fraction after combined 
treatment with docetaxel. The two survival values 
were statistically compared using analysis of vari-
ance with subsequent application of Student’s 
t-test. A more-than-additive effect was judged to 
be present if the surviving fraction measured after 
X-ray alone was greater then that measured after 
combined treatments. The required calculations 
were performed using PSI-Plot software (Polysoft-
ware International, Salt Lake City, UT, U.S.A.).
Cell cycle analysis
AGS cells were exposed to docetaxel in 25-cm
2 
ﬂ  asks at a density of 5 × 10
3 cells cm
−2 after over-
night incubation. To establish the effect of drug 
concentration on cell cycle distribution, cells were 
exposed to various docetaxel concentrations rang-
ing from 0 to 10 nM for 24 h (data not shown). 
Data from drug dose-response experiments 
together with the previously established docetaxel 
cytotoxicity data (Balcer-Kubiczek et al. 2006) 
were used to design experiments on the dependence 
of cell cycle parameters on drug exposure durations 
(described in the ﬁ  gure legend) at 3 nM. Treated 
and control cells were prepared for ﬂ  ow cytometry 
analysis by staining with propidium iodine (PI) 
using reagents and procedures in the Vermont 
Cancer Center protocol (University of Vermont, 
Burlington, VT, U.S.A.; http://www.vermontcancer.
org/research/cores/ﬂ  ow). Cells were then analyzed 
for red ﬂ  uorescence (PI) using Becton Dickenson 
FACScan machine, as described previously 
(Balcer-Kubiczek et al. 2007). For each sample, 
10,000 events were collected and analyzed. Sam-
ples were run in triplicate and experiments repeated 
three times. Relative G1, S, and G2/M populations 
expressed as percentages of the total using the 
MODFIT computer program version LT3-1 (Verify 
Software House, Topsham, ME, U.S.A.), as previ-
ously (Balcer-Kubiczek et al. 2007).
Mitotic index assessment
In the process of harvesting AGS cells for ﬂ  ow 
cytrometry analysis at each time point, aliquots of 
the cell suspensions were taken and processed for 
assessment of mitotic activity by ﬂ  uorescence 
microscopy. The mitotic index was determined by 
staining with 4’, 6-diamidino-2-phenylindole 
(DAPI; Sigma Immunochemicals, St. Louis, MO, 
U.S.A.), as previously described (Balcer-Kubiczek 
et al. 2006). In this approach, only chromatin stains 
with DAPI (at 1.5 µg/ml) ﬂ  uorescing blue. DAPI-
stained cells were scored for morphological evi-
dence of mitosis (300–500 random cells per slide, 
1500–2000 cells total), as described previously 
(Balcer-Kubiczek et al. 2006). In each of three 
independent experiments, two different observers 
evaluated the same slide and the results were 
averaged.
Multi-immunoblot analysis 
of phosphoproteins
Whole lysate protein samples were prepared from 
AGS cells after treatment with docetaxel (3 nM 
for 24 h) or at various time intervals (described in 
the ﬁ  gure legend) following 0.3 or 2 Gy using 
reagents and protocols provided by Kinexus Bio-
informatics Corporation (Vancouver, BC, CA; 
http://www.kinexus.ca/kinetworks.htm). Total 
protein was prepared as described previously 
(Balcer-Kubiczek et al. 1999). Brieﬂ  y, cells were 
washed with ice-cold PBS, scrapped in lysis buffer 
supplemented with protease and phosphatase 
inhibitors and sonicated for 15 s. Cell debris was 305
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removed by centrifugation at 100,000 rpm for 
30 min at 4 
oC. Total protein concentrations in each 
sample were determined by the Bio-Rad protein 
assay according to the manufacturer’s instructions 
(Bio-Rad Laboratories, Richmond, CA, U.S.A.). 
For the Kinetworks™ protein phosphorylation 
analysis, 25 µg of total protein per lane was 
resolved on a 13% sodium dodecyl sulfate poly-
acrylamide gel, transferred to nitrocellulose mem-
brane and probed with a custom mixture of 
32P–labeled antibodies against cyclin B1, the target 
phospho-serines on ATM, Chk1, Cdc25C or H3 
and phospho-tyrosine on Cdk1 (described in the 
introduction). The Kinetworks™ protein phos-
phorylation screens and the data analysis were 
performed by Kinexus Bioinformatics Corporation 
(Vancouver, BC, CA). The reproducibility of these 
screens was within 15%. Detailed information on 
the Kinetworks™ multi- immunoblot analysis has 
been published (Pelech, 2004; Oh et al. 2007).
Results
Single dose-response curves
Cell survival was measured for X-ray doses up to 
10 Gy using the colony-formation end point. The 
IR and LQ ﬁ  ts to low dose data are depicted in 
Figure 1. Fitting the full dose-range survival data 
using the IR model resulted in best-fit model 
parameters shown in Table 1. By the criteria 
described in Materials and Methods (i.e. αs/αr ≠ 1 
and dc ≠ 0) the AGS gastric and A549 lung adeno-
carcinoma cell lines exhibited robust HRS, whereas 
the PC3 prostate cancer cell line did not. Our esti-
mate of the dc dose of 0.11 ± 0.03 Gy for A549 
cells agrees very well with the recent estimate of 
dc of 0.10 to 0.18 cGy for this cell line (Enns et al. 
2004). The HRS magnitude as judged by the slope 
ratio αs/αr for A549 cells (Table 1) was 2–3 times 
greater than the previously reported value of 4 to 
5 (Joiner et al. 2001). The dc dose of 0.30 ± 0.05 
Gy was calculated for the AGS cell line. The HRS 
status of the PC3 cell line remains uncertain since 
the contradictory results were obtained in the pres-
ent vs Gray Laboratory studies (Joiner et al. 2001). 
Table 1 also shows the values of surviving fractions 
at 2 Gy (SF2) as well as best-ﬁ  t parameters of the 
LQ model. SF2 is a measure of radiation sensitiv-
ity. By this criterion, HRS positive cell lines sig-
niﬁ  cantly differed in the intrinsic sensitivity, with 
A549 cells being two-fold more radioresistent than 
AGS cells. Thus, our results with HRS positive 
cell lines are consistent with the previously 
suggested correlation between SF2 and αs/αr 
(Joiner et al. 2001; Mothersill et al. 2002).
Time course of docetaxel-induced 
effect on AGS cell cycle distribution
Our preceding experiments showed that following 
a 24-h treatment, the percentage of AGS cells in 
the G2/M phase increased from ∼20% to 75% with 
docetaxel concentrations up to ∼3 nM and reached 
a near-plateau at docetaxel concentrations 3 nM. 
Based on this observation and our previous 
docetaxel cytotocity data for AGS cells (Balcer-
Kubiczek et al. 2006) we selected 3 nM for time 
course studies of cell kinetics. Four hours after the 
beginning of treatment at 3 nM the proportion of 
AGS cells in G2/M increased approximately two-
fold and by 24 h ∼71% of the cells were in G2/M, 
compared to un-treated control cells (Fig. 2). The 
G2/M arrest was not complete, however, because 
the remaining ∼30% of the cells were approxi-
mately equally distributed between the S- and 
G1-phases (∼14% and ∼15%, respectively). The 
direct counts of mitotic ﬁ  gures in the samples 
concurrently analyzed by ﬂ  ow cytometry (numbers 
in Fig. 2) demonstrated a modest increase of 
mitotic cells among cells with a G2/M DNA content 
(mitotic index of ∼3% following 3 nM docetaxel 
for 24 h, compared to ∼1.5% in non-treated control 
Table 1. Values of the parameters in the induced repair 
model and the linear quadratic model ﬁ  tted to the data 
for each cell line (AGS, A549, PC3) tested for the 
presence of radiation hypersensitivity in the low-dose 
region.
Model AGS A549 PC3
IR (induced
repair)
αs (Gy
−1) 1.36 ± 0.03 1.66 ± 0.04  0.88 ± 0.43
αr (Gy
−1) 0.17 ± 0.08 0.14 ± 0.02 0.26 ± 0.02
dc (Gy) 0.30 ± 0.05 0.11 ± 0.03 0.14 ± 0.07
β (Gy
−2) 0.19 ± 0.04 0.04 ± 0.00 0.06 ± 0.01
αs/αr 8.1 ± 1.1 11.5 ± 1.3 3.4 ± 1.7
LQ (linear
quadratic)
α (Gy
−1) 0.38 ± 0.03 0.19 ± 0.02 0.33 ± 0.04
β (Gy
−2) 0.11 ± 0.01 0.03 ± 0.01 0.04 ± 0.01
SF2 0.30 ± 0.01 0.60 ± 0.02 0.44 ± 0.03306
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cells. This result indicates substantial enrichment 
in G2 at various time points after 3 nM of 
docetaxel.
Effect on AGS cells of X-irradiation 
(0.3 or 2 Gy) without or with
docetaxel pre-treatment
To test whether the HRS magnitude is inﬂ  uenced 
by the proportion of AGS cells in G2, we pre-
treated cultures with 3 nM docetaxel for 0, 4 or 24 
h and measured clonogenic survival for docetaxel 
alone or in combination with 0, 0.3 or 2 Gy X-rays 
given immediately at the end of a docetaxel time 
course. Docetaxel toxicity increased with time in 
the drug at 3 nM and resulted in surviving fractions 
of 0.98 ± 0.02 at 0-h, 0.36 ± 0.04 at 4-h and 0.014 ± 
0.005 at 24-h time points. Within the same exper-
iment, two additional drug-exposed groups were 
irradiated with 0, 0.3 or 2 Gy over a drug-time 
course and assayed for survival. The combined –
treatment normalized data (see Materials and 
Methods) and X-ray only data are shown in 
Figure 3. There are two points to note. First, the 
X-ray-only data in Figure 3 independently con-
firmed and extended the initial AGS data in 
Figure 1. Based on the IR model parameters for 
the AGS cell line in Table 1, the predicted survival 
fraction at 0.3 Gy was 0.82 vs 0.86 ± 0.08, a 
weighted mean of surviving fractions at 0.3 Gy 
Figure 1. The low-dose portions of the clonogenic survival curves (0.05–1.5 Gy) for human non-small cell lung (A549), gastric (AGS) or 
prostate (PC3) cancer-derived cells X-irradiated with single doses between 0.05–10 Gy. Solid line: the least-square ﬁ  t to the induced repair 
(IR) model; Broken line: the least-square ﬁ  t to the linear-quadratic model. IR or LQ model parameters based on the full-dose range 
(0.05–10 Gy) data are listed in Table 1 Points: the mean surviving fractions; Bars: standard errors of the mean from 12–15 replicate 
experiments.307
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measured at 0, 4, 24 h time points. Second, referring 
next to the X-ray plus docetaxel survival data, 0.3 
Gy X rays preceded by docetaxel pre-treatment for 
24 h produced a robust synergistic effect (p = 0.003, 
one tail t-test) whereas all the other conditions 
produced an additive effect between docetaxel and 
radiation (p  0.3, one-tail t-test).
Activation of the ATM kinase
and G2 checkpoint proteins by
radiation and docetaxel in AGS cells
To test whether ATM and an ATM signaling path-
way play a role in HRS we compared early 
responses of ATM and G2 checkpoint proteins to 
the HRS dose of 0.3 Gy vs 2 Gy as a function of 
time. In view of the observed synergy between 
docetaxel and radiation we also investigated ATM 
and G2 checkpoint proteins after a prolonged 24-h 
docetaxel exposure at 3 nM. We ﬁ  rst describe the 
ATM/Chk1/Cdc25C/Cdk1 pathway (Fig. 4). The 
data in Figure 4 were normalized to the total activ-
ity in each lane to emphasize temporal effects and 
to facilitate comparisons across the protein data 
sets. Both 0.3 Gy and 2 Gy induced ATM phos-
phorylation on S1981 that peaked at 30-min and 
remained elevated 1-h after irradiation. Compared 
to control values, peak induction levels were a 3- or 
10-fold at 0.3 or 2 Gy, respectively. We found that 
phosphorylation of Chk1 was 2- to 3-fold higher 
in the two dose groups, compared to controls, and 
maintained for up 1 h. Similar phosphorylation 
patterns were observed in responses of Cdc25C 
and Cdk1 (Fig. 4). Exposure to docetaxel had no 
effect on the kinase activity of the ATM, Chk1, 
Cdc25C or the expression of Cdk1.
To further evaluate G2 checkpoint, we assessed 
markers of mitotic cells, i.e. the degree of H3 his-
tone phosphorylation and expression of cyclin B1 
(Fig. 5). While phosphorylation of Chk1, Cdc25C 
and Cdk1 continued to rise during the 1 h post-
irradiation period, a decrease in mitotic activity in 
the two dose groups was evident only at a 1-h time 
points. Collectively, the data in Figure 4 and 5 are 
consistent with transient early G2 checkpoint 
responses to 0.3 or 2 Gy of X rays. The duration 
of this G2 checkpoint was weakly dose-dependent. 
In the case of docetaxel, no correlation was 
observed between the expression of cyclin B1 and 
the degree of H3 phosphorylation (Fig. 5).
Discussion
We have identiﬁ  ed the gastric cancer-derived AGS 
cell line as HRS positive with the dc dose of ~0.3 
Gy and demonstrated the combination of docetaxel 
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and 0.3 Gy X-rays is synergistic. This finding 
distinguishes low radiation dose chemoradiation 
with docetaxel from conventional chemoradiation 
therapy since docetaxel produces an additive effect 
with higher (1 Gy) radiation doses, as exempliﬁ  ed 
by the 2 Gy data (Fig. 3). The docetaxel concentra-
tion of 3 nM corresponds to plasma levels of 
docetaxel out to 24–72 h after the end of the dose 
and administration schedule used in routine clinical 
practice i.e. 60–100 mg/m
2 given over 1 h by infu-
sion (Gustafson et al. 2003; Andersen et al. 2006).
Although HRS varied among the three lines 
tested, the maximum low-dose hypersensitivity 
was observed in the dose range of ∼0.1 –0.3 Gy 
(Table 1, Fig. 1), in agreement with previous 
reports (Joiner et al. 2001; Chandna et al. 2002; 
Short et al. 2003; Enns et al. 2004; Short et al. 
2005); however, our estimates of the IR model 
parameters for A549 or PC3 cells (Table 1) differ 
from those in previous reports (Joiner et al. 2001). 
This may be due in part to different techniques 
used to determine cell survival. An important 
methodological point about our data is that we used 
the standard colony-forming assay; by this 
approach survival curves can be determined down 
to several logs of cell killing. In contrast, the major-
ity of previous HRS studies used their own 
laboratory-specific methods including the cell 
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sorter-based plating technique combined with 
micro-image analysis to quantify colony formation 
(Short et al. 1998) or the single-cell gel micro-
encapsulation technique combined with flow 
cytometry to quantify proliferation of irradiated 
cells (Bogen et al. 2001; Enns et al. 2004). One 
disadvantage of these approaches is that cells are 
subjected to chemical and/or physical stress that 
may inﬂ  uence survival results in the low-dose 
range. In addition, the use of these assays concen-
trates on the ﬁ  rst log of cell killing and high-dose 
portions of survival curves are obtained by differ-
ent methods (Short et al. 1998) or not established 
(Enns et al. 2004). In the latter case the four IR 
model parameters cannot be obtained with any 
statistical certainty, as only a few low-dose survival 
data are available.
We provided circumstantial evidence (Fig. 3) 
that G2/M cells are more sensitive to low radiation 
doses than exponentially growing cells, because 
we observed an enhancement of HRS in the AGS 
cell populations partially synchronized at G2 phase 
(Fig. 2). To within statistical uncertainties enrich-
ment for G2 cells by 3 nM docetaxel for 24 h 
(71% ± 4%) was similar to that by ﬂ  ow cytometry-
based phase sorting in the Short study (conﬁ  dence 
limits 74%–85%) (Short et al. 2003). Referring 
again to Figure 3, a 4-h drug exposure resulted in 
∼40% G2 enrichment but had no effect on the 
magnitude of HRS. We speculate that the duration 
of cell holding at G2 is a more critical variable than 
the actual proportion of cells at G2 at time of irra-
diation. Our interpretation is based on checkpoint 
adaptation, a phenomenon in which cells arrested 
in a checkpoint eventually override this arrest and 
re-enter the cell cycle despite the fact they have 
not repaired the damage that elicited the arrest. 
Adaptation to the G2 checkpoint has been docu-
mented to occur spontaneously as well as in a 
response to several forms of DNA damaging 
agents, including ionizing radiation (Syljuåsen 
et al. 2003; Deckbar et al. 2007), and prolonged 
administration of docetaxel at low concentrations 
(Abal et al. 2003; Morse et al. 2005; Balcer-Kubic-
zek et al. 2006; Hernández-Vargas et al. 2007). A 
2-fold increase in mitotic index after 24 h in 
docetaxel (Fig. 2) is consistent with G2 checkpoint 
release despite the presence of damage to the 
mitotic apparatus; no effect of adaptation is seen in 
our 4-h data (mitotic indices 1.5% ± 0.2% vs 
1.4% ± 0.1%, at 0 or 4-h in docetaxel, respectively. 
The three studies (Chandra et al. 2002; Short et al. 
2003; Enns et al. 2004) reported conﬂ  icting effects 
of cell cycle on HRS, but no experimental details 
were provided to permit the analysis of these ﬁ  nd-
ings in terms of checkpoint adaptation.
The data in Figures 4 and 5 are inconsistent 
with the hypothesis that enhanced sensitivity of 
G2/M phase cells to low radiation doses is 
associated with the abrogation of the early G2 
checkpoint (Marples et al. 2003). Rather our data 
suggest a dose-dependent transient checkpoint 
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response in G2 followed by mitotic delay shortly 
(1h) after irradiation of HRS-positive AGS 
cells. Similar conclusions were published recently 
(Enns et al. 2004; Short et al. 2005). X-irradiation 
of AGS cells led to concurrent activation of ATM 
and three additional proteins (Chk1, Cdc25C and 
Cdk1) thought to play critical roles in the preven-
tion of premature mitosis. Our data are in 
agreement with those that have correlated phos-
phorylation of these proteins with DNA damage-
induced G2 checkpoint (Fournari et al. 1997; 
Sanchez et al. 1997; Peng et al. 1997; Short et al. 
2005). In addition, our data are consistent with 
the hypothesis that DNA double-strand breaks 
(DSBs) are lesions activating the ATM kinase 
activity followed by ATM-dependent modiﬁ  ca-
tions of G2 checkpoint proteins (Bakkenist and 
Kastan, 2003; Buscemi et al. 2004; Deckbar et al. 
2007). X-ray doses of 0.3 or 2 Gy induce DSBs 
per cell  respectively, whereas docetaxel at low 
concentrations does not induce DSBs (Rothkamm 
and Löbrich, 2003, our data not shown). The 
mitotic cell markers commonly used to monitor 
entry into mitosis, the expression of H3 S10 and 
cyclin B1, declined as a function of time after 
X-irradiation, but the effect was less pronounced 
at 0.3 Gy than at 2 Gy (Fig. 5). This is the oppo-
site of the Marples ﬁ  ndings (Marples et al. 2003) 
that show no dose-dependent decrease in mitotic 
indices after radiation exposure 0.6 Gy, i.e. a 
dose threshold for G2 checkpoint activation in 
HRS positive cell lines. The data supporting this 
conclusion were obtained 2-h post-irradiation, 
which is past the duration of the early G2 arrest 
in the majority of ATM-positive cell lines (Xu 
et al. 2001, 2002). With regard to the effect of 
docetaxel on the cell cycle distribution (Fig. 5), 
a 2-fold increase in the expression of cyclin B1 
following 24-h docetaxel treatment vs control 
agrees well with our estimate of the mitotic index 
by direct counting of mitotic figures in DAPI 
stained nuclei (Fig. 2). A lack of the expression of 
H3 S10 may seem inconsistent with these data. 
However, it has been demonstrated that the two 
molecular markers of mitotic cells identify different 
mitotic subpopulations (Juan et al. 1997). Whereas 
cyclin B1 is expressed throughout mitosis, docetaxel 
targets cells in metaphase, which is past the initia-
tion of H3 phosphorylation in prophase (Juan et al. 
1997; Prigent and Dimitrov, 2003).
In conclusion, the results of the present study 
support the existence of HRS in gastric and non-small 
cell lung cancer cell lines. Clonogenic death of gas-
tric cancer cells by low radiation doses was signiﬁ  -
cantly enhanced by a prolonged pre-treatment with 
low concentrations of docetaxel. In our cellular 
model, HRS did not correlate with the ATM/Chk1-
regulated early G2 checkpoint arrest. Our results also 
suggest a new approach for the improvement the 
effectiveness of docetaxel-based radiotherapy of 
gastric cancer using low doses per fraction.
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